

1 **Title**

2 Efficacy of baths with mineral-medicinal water in patients with fibromyalgia: a randomized clinical trial

3 **Authors**

4 María Reyes Pérez-Fernández<sup>a</sup>

5 Natalia Calvo Ayuso<sup>a</sup>

6 Cristina Martínez Reglero<sup>b</sup>

7 Ángel Salgado Barreira<sup>b</sup>

8 José Luis Muiño López-Álvarez<sup>c</sup>

9 **Affiliation and addresses:**

10 <sup>a</sup>Escuela Universitaria de Enfermería de Ourense, SERGAS. Universidad de Vigo. Ourense. España

11 <sup>b</sup>Unidad de Metodología y Estadística. Instituto de Investigación Sanitaria Galicia Sur. Vigo. España

12 <sup>c</sup>Centro de salud “A Cuña-Mariñamansa”, SERGAS. Ourense. España

13 Correspondence address:

14 María Reyes Pérez Fernández

15 Escuela U. Enfermería. Complejo Hospitalario Universitario de Ourense

16 C/ Ramón Puga 52-54. 32005, Ourense España

17 [mariareyes.perez.fernandez@sergas.es](mailto:mariareyes.perez.fernandez@sergas.es)

18 Phone number: +34 988 388403/676520946

1 Efficacy of baths with mineral-medicinal water in patients with fibromyalgia: a randomized clinical trial

## 2 **Summary:**

3 The layout of this study, designed as a randomized crossover clinical trial, is to evaluate the efficacy of an  
4 intervention with mineral-medicinal water from As Burgas (Ourense) in patients suffering from  
5 fibromyalgia. **Pre-intervention:** randomization of group A and group B. **Intervention:** Phase 1: Group A: 14  
6 baths in thermal water for a month and standard pharmacological treatment; group B, standard  
7 pharmacological treatment. Rest period, 3 months. Phase 2: Group A, standard treatment and Group B, 14  
8 baths in thermal water for a month plus standard treatment. The Fibromyalgia Impact Questionnaire (FIQ)  
9 was used; this grades from 1 (minimum) to 10 (maximum) the impact of the illness, which was measured in  
10 both phases. 25 patients were included in each group and the study was concluded with 20 patients in group  
11 A and 20 in group B. The intervention group obtained, once the baths finished, a mean score of 60,3 ( $\pm 11,8$ )  
12 and the control group of 70,8 ( $\pm 13,0$ ) ( $p < 0,001$ ). Three months later, the intervention group presented a  
13 mean score of 64,4 ( $\pm 10,6$ ) and the control group of 5,0 ( $\pm 11,3$ ) ( $p < 0,001$ ). We can therefore conclude that  
14 the simple baths with mineral-medicinal water from As Burgas can make an improvement on the impact  
15 caused by fibromyalgia.

## 16 **Keywords**

17 Clinical trial, mineral waters, fibromyalgia, balneology, rheumatic diseases

## 18 **INTRODUCTION**

19 Fibromyalgia is, still nowadays, a syndrome with little known aetiology, characterized by generalized  
20 skeletal muscle pain accompanied by other diverse symptoms, such as fatigue, sleep disturbances and  
21 anxiety and depression issues, among others (Wolfe et al. 2013). Its treatment is usually complex  
22 (Macfarlane et al., 2017) and, in many occasions, unsatisfactory, placing the FM as a public health problem  
23 due to the significant health expenditure generated, which is mainly translated in a high rate of medical  
24 consultations and a high consumption of drugs (Arnold et al., 2018).

25 Taking into account the chronicity and idiopathic origin of this syndrome, the primary aim of treatment  
26 should be focused on improving the quality of life of patients, and evidence makes clear the need to combine  
27 pharmacological treatments with non-pharmacological ones (Häuser et al., 2012). Among these last ones,  
28 balneotherapy has been proved an effective strategy in the treatment of chronic pain (Morer et al. 2017;  
29 Karagulle et al 2017). It is a safe therapeutic option, with little adverse effects (Langhorst et al., 2009) and  
30 usually well tolerated by patients, providing analgesia, sedation and muscular rejuvenation (Naumann et al.  
31 Sadaghiani, 2014), which has great importance in this pathology.

32 The main aim of this study is to assess the efficacy of an intervention with mineral-medicinal water in  
33 patients with fibromyalgia, which could lead to a clinically relevant reduction in parameters of affectation at  
34 the end of the intervention and after one month, measured with the Fibromyalgia Impact Questionnaire  
35 (FIQ). As secondary objectives, positive changes in hemodynamic variables (systolic, diastolic and pulse

1 pressure), drug consumption and allodynia will be evaluated.

## 2 **MATERIALS AND METHODS**

### 3 **Study design and patient selection:**

4 A randomized crossover clinical trial (RCT) was proposed, being developed between January 2016 and  
5 January 2017. The study was approved by the Autonomous Committee of Research Ethics of Galicia  
6 (Registration Code 2016/362).

7 Patients were invited to participate by the doctors and nurses from a health centre in the city of Ourense. In  
8 case of acceptance, an appointment to a consultation with two nurses that were members of the research  
9 team, would be set. Once there, they would be provided with the information sheet and the informed consent  
10 form that needed to be signed. At that point the measurements would be taken. Furthermore, they were  
11 provided with health education guidelines, emphasizing the benefits of the abandonment of certain harmful  
12 behaviours, especially sedentary lifestyle.

### 13 **Participants: inclusion and exclusion criteria**

14 Male and female patients aged between 18 and 65 and diagnosed with FM according to the criteria of the  
15 American College of Rheumatology of 2010, were included (Wolfe et al., 2010), excluding those who had  
16 absolute or relative contraindications for taking baths of MM water: acute phase illnesses, tumours, cardiac,  
17 respiratory or renal terminal insufficiencies, severe metabolic disorders, severe or decompensated arterial  
18 hypertension and recent cerebrovascular accidents, also post-traumatic and postoperative processes,  
19 hypotension, vascular pathologies, history of fractures due to osteoporosis or uncontrolled thyroid diseases  
20 (Bazzichi et al 2013, Fazaa et al 2014, Bağdatlı et al 2015, Branco et al 2016, Fioravanti et al.2018). We also  
21 excluded patients who had taken baths with MM water during the last year, those who suffered from  
22 psychiatric or cognitive disorders, had a disability that limited their participation, pregnant women, those  
23 who had taken part in other clinical trial and patients who did not consent to participate.

### 24 **Intervention**

25 The sample was randomly divided into two groups: group A and group B. The study was, likewise, divided  
26 into two phases:

27 Phase 1: The patients of group A took 14 baths, 30 minutes long for a month, in bicarbonated sodium water  
28 of medium mineralization, alkaline, lithic, fluorinated, silicated, with a temperature of 38°C in the thermal  
29 and public pool of As Burgas (Ourense), while they carried on taking the treatment prescribed by their  
30 doctor. On the other hand, patients in group B only followed the usual pharmacological treatment prescribed  
31 by their doctor that they were already taking before the study commenced.

32 The two groups were subjected to four measurements: baseline, a measurement when group A finished the  
33 baths, another one a month later and the last one, three months after receiving the baths. Subsequently, the  
34 entire sample maintained a 3-month washout period. This washout period was planned so that there were no  
35 residual therapeutic effects of the baths in Group A before starting the second phase of the trial, and it was

1 made based on other study results (Bağdatlı et al., 2015, Koçyiğit et al., 2016), all of them RCTs of parallel  
2 groups, since no studies with a cross design that could be used as a model were found.

3 Phase 2: Once the washout period was completed, the baseline measurements were again collected from the  
4 two groups of participants. Subsequently, the groups were crossed. Thus, only group A carried on with its  
5 usual pharmacological treatment and patients from group B received the same intervention in As Burgas  
6 thermal pool as group A in the first phase, in addition to continuing with the treatment prescribed by the  
7 doctor. The two groups were once again measured at the end of group B baths, 1 month after and 3 months  
8 later.

9 From the beginning of the study and throughout it, and with the aim of not masking the pain, clear  
10 instructions were given to the patients to not take symptomatic drugs ± one day before the different check-  
11 ups. Likewise, they were told to not start any non-pharmacological therapy that could alter the results of the  
12 study.

### 13 **Studied variables**

14 Sociodemographic and epidemiological data, such as sex, age, marital status, studies, occupation, smoking  
15 habits or body mass index, were collected. As a primary outcome, the clinically relevant reduction in the  
16 affectation parameters was suggested, being this measured with the FIQ. As secondary outcomes, we  
17 considered the positive changes in the hemodynamic variables (systolic and diastolic blood pressure and  
18 heart rate measured with the Omrom M-2 tensiometer), the intake of drugs for FM (grouping them in  
19 analgesics, antidepressants, anticonvulsants and muscle relaxants) and allodynia, measured with the Omrom  
20 M-2 blood pressure cuff, which measures the intensity of the stimulus needed to produce pain and, the lowest  
21 this is, the highest is the allodynia index (Chandran et al 2012; Cassis et al 2014). To measure the primary  
22 outcome, the fibromyalgia impact, the FIQ questionnaire was used. This questionnaire is a validated  
23 instrument that assesses the impact of fibromyalgia over physical capacity, such as subjective signs closely  
24 related to this syndrome (Salgueiro et al. 2013). The scoring range goes from 1 to 100, with 1 being the  
25 highest functional capacity and quality of life (minimum impact of fibromyalgia) and 100 the maximum  
26 impact.

### 27 **Sample size and randomization**

28 The sample size was calculated based on the study by Bagdatli et al. (2015), in which an average FIQ score  
29 of 51.2 points was observed in the experimental group before the intervention and a reduction of the score  
30 close to 12 points after the intervention. According to this, we estimated an average post-intervention FIQ  
31 score of 39.0 points and standard deviation of the difference of 18.0 points. Under these assumptions, to  
32 achieve a power of the 80% to detect differences in the contrast of the hypothesis by a comparison test of  
33 means for two related samples, taking into account a level of significance of 5%, 20 pairs of subjects were  
34 needed in the study. Assuming a percentage of losses and/or dropouts of 20%, it was necessary to recruit 25  
35 pairs of subjects. The recruitment period was carried out during the months of January and February 2016.  
36 The first 50 patients who met the inclusion criteria and who agreed to participate were included in the study.

1 For the allocation of patients to one of the two groups, a randomization list generated automatically by an  
2 outside collaborator was used, keeping the sequence hidden for the research team until the intervention was  
3 assigned. The study was open, so there was no blinding of the participants or the researchers regarding the  
4 assigned group, nor in the evaluation of the results. However, monitoring was carried out by internal and  
5 external auditors to guarantee the quality of the data.

## 6 **Statistic analysis**

7 Descriptive analyses were performed (expressing the continuous variables in mean and standard deviation  
8 (SD) and qualitative variables in absolute numbers and percentages) and comparison tests (Student's t test for  
9 independent and paired samples and McNemar test), as well as normality tests of continuous variables  
10 (Shapiro-Wilks test). If the last ones did not present a normal distribution, the non parametric tests of Mann-  
11 Whitney and Wilconxon were used. Intention-to-treat analyses were conducted to keep the advantages of  
12 randomization regarding known or unknown variables that could influence the results, and analysis by  
13 protocol. The study losses were analysed separately. The analyses were performed with the software SPSS  
14 version 19.

15

## 16 **RESULTS**

17 Of the 191 men and women from the health centre diagnosed with FM, 106 (75.2%) did not meet the  
18 inclusion criteria, 20 (14.2%) could not be contacted and 15 (10.6%) did not accept to participate. 50 were  
19 the individuals that started the study, finalizing 41 of them, with a total percentage of losses of the 18%, (4  
20 subjects in group A and 5 subjects in group B), not observing significant differences between the lost sample  
21 and the one that carried on with the study. Amongst the lost cases, 6 f them left due to work causes, 2 due to  
22 illness and 1 due to pregnancy. Figure 1 shows the flow of participants in each stage of the trial according to  
23 the CONSORT diagram.

24 The subjects were mostly women, 48 (96%), with an average age of  $52.9 \pm 9.9$ , were married or lived as a  
25 couple 35 (70%), had secondary school education 29 (58%) and 25 (50%) were active (50%). Their mean  
26 BMI was  $28.1 \pm 4.6$ , 13 of the subjects smoked (26%), and had an average evolution of the disease of 14.2  
27 years since the diagnosis  $\pm 4.0$ .

28 Initially, the homogeneity of the sample was checked after the random assignment of the subjects in the 2  
29 groups, not observing statistically significant differences between them, except the systolic blood pressure ( $p$   
30 = 0.026), the intake of muscle relaxant drugs ( $p = 0.042$ ) and the intake of anticonvulsant drugs ( $p = 0.047$ )  
31 (table 1).

## 32 **Intra-groups comparison**

### 33 *FIQ results*

34 By analysing group A results in the two phases of the study, we can observe that in both, first and second  
35 phases, the FIQ score means after the 3 month washout period, have remained statistically significantly  
36 lower than the baseline mean in the first phase; except the last measurement 11 months after receiving the  
37 baths. In the first phase of the study, group A baseline mean was  $79.4 \pm 10.2$ , being  $61.9 \pm 13.0$  ( $p < 0.001$ ) at  
38 the end of the baths;  $66, 3 \pm 12.9$  ( $p < 0.001$ ) one month after and  $64.2 \pm 11.0$  ( $p < 0.001$ ) tree months later.

1 During the second phase, when group A was the control, the score was  $64.4 \pm 8.7$  ( $p < 0.001$ ) after the  
2 baseline measurement (performed 6 months after receiving the baths). The following measurement in this  
3 group, 7 months after receiving the baths, was  $64.6 \pm 11.5$  ( $p < 0.001$ ), the next one, 8 months later, was  $68.2$   
4  $\pm 12.3$  ( $p = 0.002$ ) and the last measurement, 11 months after receiving the baths, was  $74.0 \pm 10.0$  ( $p =$   
5  $0.070$ ).

6 On the other hand, group B FIQ score means, being this group not subjected to any intervention during the  
7 first phase of the study, did not show significant changes, with a baseline measurement of  $74.2 \pm 11.3$  at the  
8 beginning of the study,  $77.4 \pm 11.3$  ( $p = 0.304$ ) when group A finished the baths,  $73.8 \pm 17.5$  ( $p = 0.936$ ) one  
9 month after and  $76.2 \pm 12.8$  ( $p = 0.551$ ) three months later. During the second phase of the study, the  
10 baseline measurement after the washout period was  $77.3 \pm 6.7$  ( $p = 0.145$ ). It was during this phase when  
11 both groups were crossed, being group B the intervention target with mineral medicinal water baths. Thus, just  
12 at the end of the baths the average score was  $58.7 \pm 10.5$  ( $p < 0.001$ );  $63.7 \pm 9.8$  ( $p = 0.002$ ) one month after  
13 and  $64.7 \pm 10.6$  ( $p = 0.020$ ) three months later.

#### 14 *Allodynia results*

15 On top of this, the allodynia results in group A also showed significant changes like the FIQ ones; however,  
16 as it can be observed in figure 3.

17 A carry-over effect was observed in the design of the study, since group A, the one that started the  
18 intervention with baths in Phase 1, maintained, after the bleaching period in the second phase of the study, in  
19 the which it acted as control group, improvements in both aspects, since the differences in the FIQ and  
20 allodynia means were significant, compared with the first baseline measurement in the first phase, as it can  
21 be observed in figures 2 and 3.

### 22 **Inter-groups comparison**

#### 23 *FIQ results*

24 The main objective of the study, the impact of fibromyalgia measured with the FIQ questionnaire in the three  
25 measurements carried out (just after the baths, one month and three months later) to the two groups (control  
26 and intervention with baths) during both phases (first and second), show that the impact on the group that  
27 was taking the baths was always lower (table 2 and figure 4). The average score in the control group at the  
28 end of the baths was  $70.9 \pm 13.0$  and  $60.4 \pm 11.8$  in the group taking the baths ( $p < 0.001$ ). The mean score  
29 was  $71.3 \pm 15.1$  in the control group a month later and  $65$  in the group taking the baths  $\pm 11.4$  ( $p < 0.001$ ).  
30 Three months after the baths were finished, the control group showed an average score of  $75.0 \pm 11.4$  and the  
31 group that took the baths, of  $64.4 \pm 10.7$  ( $p < 0.001$ ).

#### 32 *Allodynia results*

33 In regards to one of the secondary objectives, the improvement or increase of the mean in the allodynia data,  
34 we were able to observe that just at the end of the baths and one month later, both groups did not show  
35 statistically significant differences. However, three months after the intervention the group subjected to the  
36 baths presented a significant improvement against the other group, as it can be observed in table 2 and figure  
37 5.

1 Regarding the other variables, such as hemodynamic values and drug intake, no significant differences were  
2 observed in the different measurements carried out throughout the study.

### 3 **DISCUSSION**

4 In the present study, after the administration of a protocol of baths with MM water to patients diagnosed with  
5 FM, a significant improvement in the impact caused by the disease was found. This was measured with the  
6 FIQ questionnaire several months after the intervention. Our study is the first one to use a crossover RCT  
7 design to measure the therapeutic use of MM baths in patients with fibromyalgia. The choice of this type of  
8 design was to give scientific value to a type of co adjuvant therapy that, in our environment and until now,  
9 has not been taken into sufficient consideration by health professionals.

10 A consensus on the therapeutic management of fibromyalgia has been reached (McFarlane et al., 2017),  
11 highlighting the importance of the multidisciplinary approach and giving special emphasis to non-  
12 pharmacological treatments; and even more recently, an evidence-based diagnostic system for this illness has  
13 been established, based on the ACTION-APS taxonomy (Arnold et al., 2018). This taxonomy includes  
14 mechanisms, common characteristics, comorbidities and diagnostic criteria that could improve the  
15 recognition of FM in clinical practice.

16 FM has been suggested to be a clinical manifestation of central nervous system hypersensitivity (Yunus et  
17 al., 2008), being this hypersensitivity the main mechanism involved in the development and maintenance of  
18 chronic pain (Woodman, 2013). There is evidence of altered central pain pathways, suggesting that stress  
19 peptides that trigger the release of inflammatory and neurosensitising mediators take part in  
20 neuroinflammation (Theoharides et al., 2015). The immersion in mineral-medicinal water has been proved to  
21 cause physiological effects both locally and generally, exerted by physical, chemical and biological  
22 mechanisms (Fioravanti et al., 2011; Galvez et al., 2018). Perhaps for this reason, the temperature rise and  
23 the effect of hydrostatic pressure generated by thermal baths can produce analgesia by increasing the pain  
24 threshold (Ardic et al., 2007). These findings have been confirmed by other investigators by pointing out that  
25 in patients with fibromyalgia, a protocol of baths with water MM, can reduce certain mediators of  
26 inflammation and pain, and that this may be due to the chemical components of the water (Guidelli et al.  
27 2012). If we add to these properties its possible antioxidant action, we would have the answer to the  
28 therapeutic benefit observed (Prandelli et al. 2013).

29 Balneotherapy deserves to be currently considered as another therapy in the treatment of fibromyalgia  
30 (Forestier et al., 2017) and along this line are the studies developed by different authors. Kocyigit et al.  
31 (2016) carried out an RCT in a spa with 61 participants, all of which were provided with health education  
32 guidelines. The members of the intervention group were given a series of 21 mineromedicinal water baths of  
33 20 minutes of duration 5 days a week. The control group carried on with the usual treatment. Pre-  
34 intervention measurements were carried out; and also after 15 days, a month and 3 and 6 months later, finding  
35 a significant improvement in the impact caused by the disease on the group having the baths against the  
36 control group up to 3 months after the intervention. 100 patients took part in the study by Fioravanti et al.

1 (2018) it was also carried out in a spa and measurements were taken in the same time intervals as those by  
2 Kocyigit; however, there were no more similarities between the two studies. This has been the first double  
3 blind study on FM balneotherapy that has been done so far. The intervention group received 12 baths with  
4 MM water for 2 weeks. The baths had a duration of 15 minutes followed by a 15 minute rest. On the other  
5 hand, the control group also received 12 baths of 15 minutes duration and 15 minutes rest, but the baths  
6 were, in this case, in hot potable water that was applied a dye to simulate the color of the mineral-medicinal  
7 water. In the results, they found significant differences between both groups up to 6 months after the  
8 experiment.

9 Our results were also along line with other literature. Over three follow up months, the group that received  
10 the baths showed significant improvement compared to the control group. However, in our study, as an  
11 unforeseen finding and due to circumstances related to the design, improvement was also found after the  
12 intervention with significant results up to 8 months after it. In crossed RCTs, the tested effect must occur  
13 quickly and have a short duration, in addition to remaining stable during the two periods of the study. When  
14 choosing the design and adjusting the measurement periods and washout, other works were analyzed, all of  
15 them RCTs of parallel groups, since, as we have mentioned previously, we could not find studies with a  
16 crossover design that could serve us as a model. The consulted works carried out measurements 3 months  
17 after the interventon (Neumann et al., 2001; Buskila et al., 2001; Altan et al., 2004; Nugraha et al., 2011;  
18 Özkurt et al., 2012; Bağdatlı. et al., 2015), 4 months (Fioravanti et al., 2007), 6 months (Evcik et al., 2002;  
19 Koçyiğit et al., 2016; Fioravanti et al., 2018) and only in one study the measurements were repeated 9  
20 months later (Dönmez et al., 2005). In all these studies, it was possible to maintain a 3 month therapeutic  
21 effect mainly, reaching a maximum of 6 months in those mentioned above. For this reason, we proposed a 3  
22 month washout period in the design of this study, in order to avoid residual therapeutic effects of the baths in  
23 group A before starting the second phase of the trial. Therefore, patients in this group spent 6 months from  
24 the time they received the baths in the first phase of the study until the end of the washout period, which,  
25 according to the scientific findings made up to that moment, seemed initially enough time. However, this  
26 was not the case, given that this beneficial effect was maintained significantly up to 8 months after finishing  
27 baths with MM waters, reaching up to 11 months later (difference not statistically significant but clinically  
28 relevant). This finding revealed the inadequate design of the study. However, on the other hand, we found  
29 that simple baths in a public pool with MM water, maintained good therapeutic results for a longer period of  
30 time than in the previously mentioned studies, which leads us to affirm that MM water improved the FM  
31 symptoms in a group of patients and that this improvement could last up to 8 months.

32 This is the first international study that has been designed as a RCT in patients suffering from fibromyalgia,  
33 where the effect of the baths and the control are assessed in the same individual, obtaining this way a lower  
34 variability than if the comparison of the effect was performed in different subjects, as it is the case of parallel  
35 RCTs. However, until the present work, no parallel studies had been carried out in Spain either.

36 On the other hand, both the controls and the experimental group in a large number of the published studies,  
37 were accommodated and received the different types of interventions in spas. It has been shown that patients



1 who abandon their daily routine and are in a different environment, such as a spa, interacting and socializing  
2 with other patients can feel an improvement in the pathological processes they suffer (Baysal et al., 2018).  
3 However, in our study, the participating subjects received the baths in a public thermal pool, accessible to  
4 any citizen and to which they came only for this therapeutic activity. This last aspect of accessibility, despite  
5 being characteristic of the city where the study was carried out, is relevant from a healthcare point of view,  
6 since it outlines the possibility for health professionals of using these thermal baths as a contributing  
7 therapeutic resource for certain pathologies.

8 Among the limitations of the study, we find the lack of blinding of the patients due to it not being allowed by  
9 the intervention, since the city where it was developed, has no other spaces like the free mineral-medicinal  
10 water springs, which just have hot potable water. Another aspect is that the sample studied was not very  
11 large, but it was still possible to detect significant differences, since the proposed design allows the same  
12 sample to work with greater statistical power. On the other hand, the washout time was proven not to be  
13 sufficient, situation that caused a carry-over effect. Nevertheless, this methodological failure facilitated the  
14 verification of the long duration of the therapeutic effect provided by the MM waters. It could be interesting  
15 to carry out a follow-up of the sample to deepen in the therapeutic effect that MM water has over this  
16 pathology.

17 In conclusion, the impact caused by FM has been improved in this study by an intervention of 14 half hour  
18 baths with MM water in patients diagnosed with the illness and the improvement has lasted significantly for  
19 8 months.

## 20 **BIBLIOGRAPHY**

21 Altan L, Bingöl U, Aykac M, et al (2004) Investigation of the effects of pool-based exercise on fibromyalgia  
22 syndrome. *Rheumatol Int* 24:272-77.

23 Ardiç F, Özgen M, Aybek H, et al (2007) Effects of balneotherapy on serum IL-1, PGE2 and LTB4 levels in  
24 fibromyalgia patients. *Rheumatol Int*;27:441-46.

25 Arnold LM, Bennett RM, Crofford LJ, et al (2018) AAPT Diagnostic Criteria for Fibromyalgia. *The Journal*  
26 *of Pain*. <https://doi.org/10.1016/j.jpain.2018.10.008>

27 Bağdatlı AO, Donmez A, Eröksüz R, et al (2015) Does addition of ‘mud-pack and hot pool treatment’ to  
28 patient education make a difference in fibromyalgia patients? A randomized controlled single blind study. *Int*  
29 *J Biometeorol* 59:1905–911.

30 Baysal E, Leblebicioğlu H, Khorshid L, et al (2018) Why individuals choose balneotherapy and benefit from  
31 this kind of treatment. *Complementary Therapies in Clinical Practice* 32:157-62.

32 Branco M, Rego NN, Silva PH, et al (2016) Bath thermal waters in the treatment of knee osteoarthritis: a  
33 randomized controlled clinical trial. *Eur J Phys Rehabil Med* 52:422–30

34 Buskila D, Abu-Shakra M, Neumann L, et al (2001) Balneotherapy for fibromyalgia at the Dead Sea.  
35 *Rheumatol Int* 20:105-08.

- 1 Chandran AB, Coon CD, Martin SA, et al (2012) Sphygmomanometry-evoked allodynia in chronic pain  
2 patients with and without fibromyalgia. *Nursing Research*, 61:363-68. doi:10.1097/NNR.0b013e318259b6cc  
3 [doi]
- 4 Cassisi G, Sarzi-Puttini P, Casale R, et al (2014). Pain in fibromyalgia and related conditions. *Reumatismo*,  
5 66:72-86.
- 6 Dönmez A, Karagülle MZ, Tercan N, et al (2005) SPA therapy in fibromyalgia: a randomised controlled  
7 clinic study. *Rheumatol Int* 26:168-72.
- 8 Evcik D, Kızılay B, Gökçen E (2002) The effects of balneotherapy on fibromyalgia patients. *Rheumatol Int*  
9 22:56-9.
- 10 Fioravanti A, Perpignano G, Tirri G, et al (2007). Effects of mud-bath treatment on fibromyalgia patients: a  
11 randomized clinical trial. *Rheumatol Int* 27:1157-161.
- 12 Fioravanti A, Cantarini L, Guidelli GM, et al (2011). Mechanisms of action of spa therapies in rheumatic  
13 diseases: what scientific evidence is there? *Rheumatology international* 31:1-8.
- 14 Fioravanti A, Manica P, Bortolotti R, et al (2018) Is balneotherapy effective for fibromyalgia? Results from a  
15 6-month double-blind randomized clinical trial. *Clin Rheumatol* 37:2203-212.
- 16 Forestier R, Erol-Forestier FB, Francon A (2017) Current role for spa therapy in rheumatology. *Joint, bone,*  
17 *spine: revue du rhumatisme*, 84:9.
- 18 Galvez I, Torres-Piles S, Ortega-Rincón E (2018). Balneotherapy, immune system and stress response: a  
19 hormetic strategy? *International journal of molecular sciences* 19: 1687.
- 20 Guidelli G, Tenti S, De Nobili E, et al (2012). Fibromyalgia syndrome and spa therapy: myth or reality?  
21 *Clinical Medicine Insights: Arthritis and Musculoskeletal Disorder* 5:19-26.
- 22 Häuser W, Jung E, Erbslöh-Möller B, et al (2012). The german fibromyalgia consumer reports—a cross-  
23 sectional survey. *BMC Musculoskeletal Disorders* 13:74.
- 24 Karagülle M, Kardeş S, Karagülle MZ (2017). Real-life effectiveness of spa therapy in rheumatic and  
25 musculoskeletal diseases: a retrospective study of 819 patients. *International journal of biometeorology*,  
26 61:1945-956.
- 27 Koçyiğit BF, Gür A, Altındağ Ö, et al (2016) Comparison of education and balneotherapy efficacy in patients  
28 with fibromyalgia syndrome: A randomized, controlled clinical study. *Ağrı-The Journal of The Turkish*  
29 *Society of Algology* 28:72-8.
- 30 Langhorst J, Musial F, Klose P, et al (2009) Efficacy of hydrotherapy in fibromyalgia syndrome--a meta-  
31 analysis of randomized controlled clinical trials. *Rheumatology (Oxford)* 48:1155-159.
- 32 Macfarlane GJ, Kronisch C, Dean LE, et al (2017) EULAR revised recommendations for the management of  
33 fibromyalgia. *Ann Rheum Dis* 76:318-28.

- 1 Morer, C., Roques, CF, Françon A, et al (2017) The role of mineral elements and other chemical compounds  
2 used in balneology: data from double-blind randomized clinical trials. *International journal of*  
3 *biometeorology*, 61:2159-173.
- 4 Naumann J, Sadaghiani C (2014) Therapeutic benefit of balneotherapy and hydrotherapy in the management  
5 of fibromyalgia syndrome: a qualitative systematic review and meta-analysis of randomized controlled trials.  
6 *Arthritis Res Ther* 16:R141.
- 7 Neumann L, Sukenik S, Bolotin A, et al (2001) The effect of balneotherapy at the Dead Sea on the quality of  
8 life of patients with fibromyalgia syndrome. *Clin Rheumatol* 20:15-9.
- 9 Özkurt S, Dönmez A, Karagülle MZ, et al (2012) Balneotherapy in fibromyalgia: a single blind randomized  
10 controlled clinical study. *Rheumatol Int* 32:1949-954.
- 11 Prandelli C, Parola C, Buizza L, et al (2013) Sulphurous thermal water increases the release of the anti-  
12 inflammatory cytokine IL-10 and modulates antioxidant enzyme activity. *Int J Immunopathol Pharmacol*  
13 26:633-46.
- 14 Salgueiro M, García-Leiva JM, Ballesteros J, et al. (2013). Validation of a spanish version of the revised  
15 fibromyalgia impact questionnaire (FIQR). *Health and Quality of Life Outcomes* 11:132.
- 16 Theoharides TC, Tsilioni I, Arbetman L, et al (2015) Fibromyalgia syndrome in need of effective treatments.  
17 *J Pharmacol Exp Ther* 355:255-63.
- 18 Wolfe F, Clauw DJ, Fitzcharles M, et al (2010) The American College of Rheumatology preliminary  
19 diagnostic criteria for fibromyalgia and measurement of symptom severity. *Arthritis care & research* 62:600-  
20 10.
- 21 Wolfe F, Brähler E, Hinz A, et al (2013) Fibromyalgia prevalence, somatic symptom reporting, and the  
22 dimensionality of polysymptomatic distress: results from a survey of the general population. *Arthritis care &*  
23 *research* 65:777-85.
- 24 Woodman I (2013) Fibromyalgia: Fibromyalgia—all in the brain? *Nature Reviews Rheumatology* 9:565.
- 25 Yunus MB (2008) Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and  
26 overlapping conditions, and the related issue of disease versus illness. *Semin Arthritis Rheum* 37:339-52.